Delivery Order SPE2DB24D3013-SPE2DB25FFNWL
Award Date 7/30/25
Potential Completion Date 7/31/25
Potential Value $3.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $10,006.04 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion expected by July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (Unit of Use, 30-count) valued at $10,818.81 under firm fixed price terms. This non-set-aside, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $25,416.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor indicated for rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $70,075.90 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract carries no...
- The Defense Logistics Agency awarded a $6,223.32 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for RINVOQ ER 15 mg tablets in quantities of 30 units. The contract, which is non-set-aside and competitively awarded, carries a firm fixed price structure with performance to be completed by August 1, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $10,548.57 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $4,470.03 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor indicated for rheumatoid arthritis and other...